Genor Biopharma provides update on proposed merger and RTO

Genor Biopharma Holdings Limited has issued a monthly update regarding its proposed merger, classified as a very substantial acquisition and connected transaction, alongside a reverse takeover (RTO) involving a new listing application. The company also confirmed its application for a whitewash waiver, a special deal related to a shareholder personnel retention plan, proposed change of company name, increase in authorized share capital, and the adoption of a one-off share option plan.

The company submitted its new listing application to the Stock Exchange on April 15, 2025. The circular despatch deadline has been extended to on or before October 31, 2025, with Genor Biopharma actively addressing regulatory comments alongside its professional parties.

Shareholders and potential investors are cautioned that the merger closing is contingent on the fulfillment or waiver of merger conditions precedent, including the approval of the new listing application by the Listing Committee and the grant of the whitewash waiver by the Executive. Failure to secure these approvals would prevent the proposed merger from proceeding.